Quantcast

Latest Macula Stories

2010-03-01 14:33:09

Smoking is already a known risk factor for age-related macular degeneration, cataract and thyroid eye disease. Now, the first study to specifically examine the impact of smoking on uveitis"“inflammation of the eye's middle layer of tissue"“indicates that tobacco smoke likely plays a role in this serious eye disease, as well. In the United States about 10 percent of blindness is caused by uveitis. Researchers led by Nisha Acharya, MD, analyzed medical records for smoking status and...

2010-01-04 14:38:29

Scientists discover the relationship between 2 blood proteins plays a pivotal role in staving off the condition Researchers at University College London say they have gleaned a key insight into the molecular beginnings of age-related macular degeneration, the No. 1 cause of vision loss in the elderly, by determining how two key proteins interact to naturally prevent the onset of the condition. In a paper to be published in a forthcoming issue of the Journal of Biological Chemistry, the team...

cd1f2354e1789f41d2f1652404ce7f57
2009-12-11 12:37:07

University of Iowa researchers have found the existence of a new, rare inherited retinal disease. Now the search is on to find the genetic cause, which investigators hope will increase understanding of more common retinal diseases. The findings appeared in the Nov. 9 issue of the Archives of Ophthalmology. The macula, located within the retina, is an area of high-resolution central vision that is needed to read or drive, for example. This area is damaged in more common retinal conditions such...

2009-12-11 00:30:00

LEUVEN, Belgium, December 11 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, announces today that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD). Wet AMD affects approximately five million patients worldwide and this patient population is continuing to grow. Wet AMD occurs when...

2009-12-02 07:47:00

BIRMINGHAM, Ala., Dec. 2 /PRNewswire/ -- Adults are more likely to lose their vision than be diagnosed with cancer. For adults 65 and over, the odds of losing vision are one in three, whereas the odds of a man developing prostate cancer are one in six and odds of a woman developing breast cancer are one in nine. Vision loss threatens the overall health of aging adults by increasing the risk of injuries, depression and inability to complete daily tasks. Vision loss in adults is often...

2009-11-02 14:11:52

May have impact on use of new antiVEGF drugs Scientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular endothelial growth factor (VEGF), i.e. one that when secreted can reach other cells at a distance, the retina shows defects similar to "dry" macular degeneration, also called geographic atrophy (GA). This finding, published in the November 3, 2009 print edition of PNAS (Proceedings of the National Academy of Sciences), not only...

2009-11-02 06:30:00

Discovery may also have impact on the use of new drugs for wet macular degeneration BOSTON, Nov. 2 /PRNewswire-USNewswire/ -- Scientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular endothelial growth factor (VEGF), i.e. one that when secreted can reach other cells at a distance, the retina shows defects similar to "dry" macular degeneration, also called geographic atrophy (GA). This finding, published in the November 3, 2009...

2009-10-08 07:09:00

ORLANDO, Fla., Oct. 8 /PRNewswire/ -- Valensa International (Orlando, FL USA) announced today that it has initiated a broad out licensing effort for University of Illinois patent (US 5,527,533 and its foreign equivalents) for the use of the astaxanthin in eye healthcare dietary supplement applications. FutureBiotics (NY, USA), Swanson Health Products (ND, USA) and Life Extension Vitamins (AZ, USA) have each acquired licenses for the use of the Valensa astaxanthin patent. The patent covers...

2009-10-01 02:17:00

PARIS, Oct. 1 /PRNewswire/ -- Fovea Pharmaceuticals announced today that it has entered into a binding agreement with sanofi-aventis to sell 100% of its share to sanofi-aventis. Fovea has a portfolio of three clinical compounds, a unique technology platform and several discovery programs dedicated to back of the eye diseases. The deal is valued to a total of euro 370M, including an immediate upfront payment and subsequent milestone payments related to the progress of the clinical...

2009-09-28 08:00:00

Sponsored by Delaware Valley Retina Associates and the Macula Vision Research Foundation WEST CONSHOHOCKEN, Pa., Sept. 28 /PRNewswire-USNewswire/ -- Delaware Valley Retina Associates has joined with the Macula Vision Research Foundation (MVRF) to sponsor a SupportSight seminar in Princeton on October 10th. SupportSight is the national series of educational seminars for people affected by macular degeneration and for those who would like to learn more about this disease affecting more...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.